Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to ...

Kaken assumes ownership of Aadi Sub, including the Aadi Bioscience name, trademarks and the FYARRO ® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) business.

Stay updated on market trends for AADI. Aadi Bioscience secures ADC portfolio license, involving $44 million upfront and $805 million in milestones plus royalties.

Full Year Net Loss: $63.7 million, compared to $65.8 million in prior year. Aadi Bioscience Inc (NASDAQ:AADI) has successfully transitioned into Whitehawk Therapeutics, focusing on advanced ADC ...

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as ...

MORRISTOWN, N.J., March 3, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently ...